Roche licenses Novimmune’s anti-TLR4 antibodyRoche’s US subsidiary Genentech has acquired an exclusive option to commercialise Novimmune’s TLR4 antibody NI-0101, the very first personalised approach to treat rheumatoid arthritis. The compound has … more ➔
Mediolanum licences Apeptico’s TNF peptide Solnatide Viennese Apeptico Forschung und Entwicklung GmbH and Milan-based Mediolanum Farmaceutici S.p.A. have signed a research & development cooperation and license agreement for Apeptico’s compound so … more ➔
A fresh take on biotech?For the second time, biotech communication start-up Labiotech hosted its event LBRefresh, this year in Paris, France. Participants enjoyed panel discussions, a start-up battle and intimate fireside chats… more ➔
Bioplastics industry grapples with ignorant consumersEU consumers have minor knowledge on bioplastics but unrealistically high expectations that can not be fulfilled, researchers said at 11th European Bioplastics Conference in Berlin. more ➔
Carbios tackles marine litteringFrench Carbios has presented a process that depolymerises one of the most common non-recycled plastics polluting the oceans. more ➔
Neovacs teams up with 3PFrench immunotherapy expert Neovacs has teamed up with CDMO 3P Biopharmaceuticals for the manufacture of interferon alpha with recently licensed technology. more ➔
Kymab raises €94m for mAb pipelineUK-based biopharma group Kymab has brought a new backer from China on board. With the help from ORI Healthcare Fund, Kymab secured a US$100m Series C financing. more ➔
Proteros inks US$167m oncology pact with MSDProteros has expanded its epigenetic drug discovery services for MSD. Just one year after having signed a first R&D pact, the computational chemistry firm inked a second contract in oncolog … more ➔
Running made by biotechAdidas has presented the world’s first lightweight racing shoe made by recombinantly produced silk fibers. more ➔
Medigene offers neoantigen-specific TCRs Until mid-October, cancer immunotherapy play Medigene AG was a pure drug developer. With a potential US$1bn TCR-contract manufacturing deal with Bluebird Bio, it widened its business focus. Now, the … more ➔
